ASH 2025

This presentation analyzed maternal and fetal outcomes for patients undergoing treatment for Chronic Myeloid Leukemia (CML) with Tyrosine Kinase Inhibitor (TKI) therapy. The study focused on the clinical management of patients during pregnancy, evaluating the safety, risks, and health outcomes for both the mother and the infant when TKI therapy is involved in the treatment plan.

The research provided critical data regarding the feasibility of managing CML during pregnancy and highlighted key considerations for clinicians when balancing oncological stability with gestational health. The findings serve to guide treatment strategies and patient counseling for those navigating the complexities of CML while planning or experiencing a pregnancy.

Upcoming Events